These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Serelaxin in addition to standard therapy in acute heart failure: rationale and design of the RELAX-AHF-2 study. Teerlink JR; Voors AA; Ponikowski P; Pang PS; Greenberg BH; Filippatos G; Felker GM; Davison BA; Cotter G; Gimpelewicz C; Boer-Martins L; Wernsing M; Hua TA; Severin T; Metra M Eur J Heart Fail; 2017 Jun; 19(6):800-809. PubMed ID: 28452195 [TBL] [Abstract][Full Text] [Related]
43. Analysis of Worsening Heart Failure Events in an Integrated Health Care System. Ambrosy AP; Parikh RV; Sung SH; Tan TC; Narayanan A; Masson R; Lam PQ; Kheder K; Iwahashi A; Hardwick AB; Fitzpatrick JK; Avula HR; Selby VN; Ku IA; Shen X; Sanghera N; Cristino J; Go AS J Am Coll Cardiol; 2022 Jul; 80(2):111-122. PubMed ID: 35798445 [TBL] [Abstract][Full Text] [Related]
44. Impact of serial troponin release on outcomes in patients with acute heart failure: analysis from the PROTECT pilot study. O'Connor CM; Fiuzat M; Lombardi C; Fujita K; Jia G; Davison BA; Cleland J; Bloomfield D; Dittrich HC; Delucca P; Givertz MM; Mansoor G; Ponikowski P; Teerlink JR; Voors AA; Massie BM; Cotter G; Metra M Circ Heart Fail; 2011 Nov; 4(6):724-32. PubMed ID: 21900185 [TBL] [Abstract][Full Text] [Related]
45. Measurement of troponin and natriuretic peptides shortly after admission in patients with heart failure-does it add useful prognostic information? An analysis of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Studies (VERITAS). Cleland JGF; Teerlink JR; Davison BA; Shoaib A; Metra M; Senger S; Milo O; Cotter G; Bourge RC; Parker JD; Jondeau G; Krum H; O'Connor CM; Torre-Amione G; van Veldhuisen DJ; McMurray JJV; Eur J Heart Fail; 2017 Jun; 19(6):739-747. PubMed ID: 28296139 [TBL] [Abstract][Full Text] [Related]
46. Predictors of postdischarge outcomes from information acquired shortly after admission for acute heart failure: a report from the Placebo-Controlled Randomized Study of the Selective A1 Adenosine Receptor Antagonist Rolofylline for Patients Hospitalized With Acute Decompensated Heart Failure and Volume Overload to Assess Treatment Effect on Congestion and Renal Function (PROTECT) Study. Cleland JG; Chiswell K; Teerlink JR; Stevens S; Fiuzat M; Givertz MM; Davison BA; Mansoor GA; Ponikowski P; Voors AA; Cotter G; Metra M; Massie BM; O'Connor CM Circ Heart Fail; 2014 Jan; 7(1):76-87. PubMed ID: 24281134 [TBL] [Abstract][Full Text] [Related]
47. Association of low body temperature and poor outcomes in patients admitted with worsening heart failure: a substudy of the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) trial. Payvar S; Spertus JA; Miller AB; Casscells SW; Pang PS; Zannad F; Swedberg K; Maggioni AP; Reid KJ; Gheorghiade M; Eur J Heart Fail; 2013 Dec; 15(12):1382-9. PubMed ID: 23858000 [TBL] [Abstract][Full Text] [Related]
48. Responder to BNP-guided treatment in heart failure. The process of defining a responder. Karlström P; Dahlström U; Boman K; Alehagen U Scand Cardiovasc J; 2015; 49(6):316-24. PubMed ID: 26153427 [TBL] [Abstract][Full Text] [Related]
49. Worsening Renal Function during Management for Chronic Heart Failure with Reduced Ejection Fraction: Results From the Pro-BNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) Study. Ibrahim NE; Gaggin HK; Rabideau DJ; Gandhi PU; Mallick A; Januzzi JL J Card Fail; 2017 Feb; 23(2):121-130. PubMed ID: 27469482 [TBL] [Abstract][Full Text] [Related]
50. Characteristics and Outcomes of Patients With Heart Failure With Reduced Ejection Fraction After a Recent Worsening Heart Failure Event. Carnicelli AP; Clare R; Hofmann P; Chiswell K; DeVore AD; Vemulapalli S; Felker GM; Sarocco P; Mentz RJ J Am Heart Assoc; 2021 Sep; 10(17):e021276. PubMed ID: 34472362 [TBL] [Abstract][Full Text] [Related]
51. The PROTECT in-hospital risk model: 7-day outcome in patients hospitalized with acute heart failure and renal dysfunction. O'Connor CM; Mentz RJ; Cotter G; Metra M; Cleland JG; Davison BA; Givertz MM; Mansoor GA; Ponikowski P; Teerlink JR; Voors AA; Fiuzat M; Wojdyla D; Chiswell K; Massie BM Eur J Heart Fail; 2012 Jun; 14(6):605-12. PubMed ID: 22535795 [TBL] [Abstract][Full Text] [Related]
52. Physical activity measured with implanted devices predicts patient outcome in chronic heart failure. Conraads VM; Spruit MA; Braunschweig F; Cowie MR; Tavazzi L; Borggrefe M; Hill MR; Jacobs S; Gerritse B; van Veldhuisen DJ Circ Heart Fail; 2014 Mar; 7(2):279-87. PubMed ID: 24519908 [TBL] [Abstract][Full Text] [Related]
53. Hospitalization following an emergency-department visit for worsening heart failure: The role of left ventricular ejection fraction. Mollar A; Lorenzo M; Villaescusa A; Heredia R; Miñana G; Santas E; de la Espriella R; Sastre C; Civera J; Martínez A; Conesa A; Sanchis J; Núñez E; Bayés-Genís A; Núñez J Med Clin (Barc); 2022 Aug; 159(4):157-163. PubMed ID: 35065819 [TBL] [Abstract][Full Text] [Related]
54. Diuretic response in acute heart failure: clinical characteristics and prognostic significance. Valente MA; Voors AA; Damman K; Van Veldhuisen DJ; Massie BM; O'Connor CM; Metra M; Ponikowski P; Teerlink JR; Cotter G; Davison B; Cleland JG; Givertz MM; Bloomfield DM; Fiuzat M; Dittrich HC; Hillege HL Eur Heart J; 2014 May; 35(19):1284-93. PubMed ID: 24585267 [TBL] [Abstract][Full Text] [Related]
55. Loop diuretics, renal function and clinical outcome in patients with heart failure and reduced ejection fraction. Damman K; Kjekshus J; Wikstrand J; Cleland JG; Komajda M; Wedel H; Waagstein F; McMurray JJ Eur J Heart Fail; 2016 Mar; 18(3):328-36. PubMed ID: 26693947 [TBL] [Abstract][Full Text] [Related]
56. Implications of Serum Chloride Homeostasis in Acute Heart Failure (from ROSE-AHF). Grodin JL; Sun JL; Anstrom KJ; Chen HH; Starling RC; Testani JM; Tang WH Am J Cardiol; 2017 Jan; 119(1):78-83. PubMed ID: 27816115 [TBL] [Abstract][Full Text] [Related]
57. Serum Bicarbonate in Acute Heart Failure: Relationship to Treatment Strategies and Clinical Outcomes. Cooper LB; Mentz RJ; Gallup D; Lala A; DeVore AD; Vader JM; AbouEzzeddine OF; Bart BA; Anstrom KJ; Hernandez AF; Felker GM J Card Fail; 2016 Sep; 22(9):738-42. PubMed ID: 26777758 [TBL] [Abstract][Full Text] [Related]
59. Comparison of Outcome Adjudication by Investigators and by a Central End Point Committee in Heart Failure Trials: Experience of the SHIFT Heart Failure Study. Tyl B; Lopez Sendon J; Borer JS; Lopez De Sa E; Lerebours G; Varin C; De Montigny A; Pannaux M; Komajda M Circ Heart Fail; 2020 Jul; 13(7):e006720. PubMed ID: 32580655 [TBL] [Abstract][Full Text] [Related]
60. Secreted Frizzled Related Protein 3 in Chronic Heart Failure: Analysis from the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). Askevold ET; Gullestad L; Nymo S; Kjekshus J; Yndestad A; Latini R; Cleland JG; McMurray JJ; Aukrust P; Ueland T PLoS One; 2015; 10(8):e0133970. PubMed ID: 26288364 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]